AstraZeneca PLC (AZN) — closed signal from March 29, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 27, 2026.
Predicted vs. what happened
AZN price · publication thesis → realized outcomesplit-adjusted
$184.00 – $189.00Entry zone — fair-value band
$188.42Published — price the day we called it
$207.26Target — the price the thesis aimed for
$207.30Peak — highest point inside the window, not a realized return
$188.41Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 12 days.
Peak price
$207.30
peak on April 10, 2026 — not a realized returnPeak gain
+10%
peak, from the publication priceWindow close
$188.41
end-of-window price, context onlyDays to target
12
Window
March 29, 2026 – June 27, 2026
The thesis — published March 29, 2026
Predicted growth
+10%
over the measurement windowTarget price
$207.26
the price the thesis aimed forEntry zone
$184.00 – $189.00
the fair-value band we waited forPrice at publication
$188.42
published March 29, 2026Confidence
72%
how strongly the data lined upTimeframe
Short-term (0–3 months)
AstraZeneca is a defensive big drug company that just got positive late-stage COPD results, giving the stock a fresh growth story beyond safety. The recent small pullback suggests big investors haven't left, implying steadier near-term price behavior. However, the overall chart isn't fully healed and the stock looks pricey, so full conviction is limited.
Primary drivers
- Good COPD trial news creates a new growth story for the stock
- Seen as a defensive drug company when markets are nervy
- Wide global medicine lineup helps steady revenue over time
- Small recent drop implies large investors likely stayed invested
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.